A clinical trial taking place in Sudbury could one day help doctors around the world determine if chemotherapy is the best treatment for cancer patients. We heard more about the trial from Dr. Amadeo Parissenti. Listen (runs 8:40)
Une équipe de Sudbury derrière ce test qui prédit les taux de survie au cancer. Listen
SUDBURY, Ontario – A test developed in Sudbury is proving successful in predicting which breast cancer patients will best respond to chemotherapy and live cancer-free for a longer period of time following treatment.
Results conducted into the RNA Disruption Assay™ (RDA™) test were presented last month […]
TORONTO, Ontario – Research presented at the San Antonio Breast Cancer Symposium (SABCS) demonstrated that the RNA Disruption Assay™ (RDA™) can be highly useful in guiding chemotherapy treatment for women with breast cancer.
Dr. Amadeo Parissenti, Professor, Laurentian University and colleagues presented, “High tumor RNA disruption […]
Dr. Amadeo Parissenti, Rna Diagnostics’ Chief Scientific Officer, will present a poster entitled, “High tumor RNA disruption is associated with increased survival in patients with locally advanced breast cancer”, at theSABCS taking place in San Antonio, Texas from December 10-14. The poster session is […]
Treating pets with cancer is our first goal but studying the disease in animals benefits humans too.
A Sudbury cancer diagnostics company has been chosen for a new pilot project for emerging health-care technologies in Ontario.Rna Diagnostics, Inc. is one of three companies selected for the MaRS Excellence in Clinical Innovation and Technology Evaluation project. Read more
Rna Diagnostics, Inc. (RnaDx) has been accepted into the MaRS Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program for the clinical evaluation of their diagnostic test, RNA Disruption Assay™ (RDA™),and its impact on patient care for individuals undergoing breast cancer chemotherapy. Through EXCITE, The […]
NEW YORK (GenomeWeb News) – Canadian molecular diagnostics company Rna Diagnostics has been chosen to have its breast cancer assay evaluated by the Toronto Health Economics and Technology Assessment initiative in a multi-center clinical trial, the company said on Thursday. GenomeWeb Daily News
The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process.
EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants.